Equities Analysts Set Expectations for Nkarta Q3 Earnings
Equities analysts at Leerink Partners have raised their Q3 2025 earnings per share estimate for Nkarta, Inc. to ($0.37), up from ($0.38). The consensus estimate for the full year is ($1.70) per share. Nkarta's recent quarterly earnings beat expectations at ($0.31) per share. Analysts have varying ratings on Nkarta, with a consensus rating of "Buy" and a target price of $13.60. Nkarta's stock opened at $2.20, with a market cap of $156.27 million. The company focuses on developing natural killer cell therapies for cancer and autoimmune diseases.
Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for Nkarta in a research note issued on Wednesday, August 13th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of ($0.37) per share for the quarter, up from their prior forecast of ($0.38). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta's FY2025 earnings at ($1.48) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at ($1.71) EPS, FY2028 earnings at ($1.44) EPS and FY2029 earnings at ($1.04) EPS.
Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.06.
A number of other research analysts also recently issued reports on NKTX. Stifel Nicolaus reduced their price target on shares of Nkarta from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday. Mizuho dropped their price objective on shares of Nkarta from $16.00 to $14.00 and set an "outperform" rating on the stock in a research note on Tuesday, June 10th. William Blair restated a "market perform" rating on shares of Nkarta in a research note on Thursday, May 15th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $10.00 price target on shares of Nkarta in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $13.60.
Get Our Latest Report on Nkarta
Nkarta Stock Down 0.5%
Shares of Nkarta stock opened at $2.20 on Friday. The business has a 50-day moving average price of $1.92 and a 200 day moving average price of $1.89. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $6.63. The firm has a market cap of $156.27 million, a P/E ratio of -1.49 and a beta of 0.72.
Institutional Investors Weigh In On Nkarta
A number of hedge funds and other institutional investors have recently made changes to their positions in NKTX. Invesco Ltd. bought a new stake in Nkarta in the fourth quarter worth approximately $30,000. Wealth Enhancement Advisory Services LLC bought a new stake in Nkarta in the first quarter worth $32,000. Savant Capital LLC bought a new stake in Nkarta in the second quarter worth $36,000. ProShare Advisors LLC acquired a new position in Nkarta during the fourth quarter worth $45,000. Finally, CWM LLC raised its holdings in Nkarta by 3,437.3% during the first quarter. CWM LLC now owns 28,157 shares of the company's stock valued at $52,000 after buying an additional 27,361 shares in the last quarter. 80.54% of the stock is owned by hedge funds and other institutional investors.
About Nkarta
(Get Free Report)Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Read More
- Five stocks we like better than Nkarta
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Long-Term Dividend Buys You Can Get for Under $50
- Golden Cross Stocks: Pattern, Examples and Charts
- How AEP Became a Critical AI Infrastructure Play
- Trading Stocks: RSI and Why it's Useful
- How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Nkarta Right Now?
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
